Statin dan risiko hiperglikemia: studi praklinis post-market terkontrol
DOI:
https://doi.org/10.32504/hspj.v7i2.813Keywords:
Adverse events, hyperglycemia, preclinical, statinAbstract
Statin is highly effective in preventing atherosclerosis-cardiovascular disease due to lipid abnormality. However, the current observational study showed statin association with new-onset diabetes mellitus, although the data is still conflicting. Until recently, no controlled study compared all statin drugs with this adverse event. The study aimed to determine the statin effect on blood glucose at a moderate dose for rats within 60 days. The animals were divided into 8 groups, and each group contained three mice, namely negatives (CMC 1%), simvastatin (0.052 mg/20 g BW of mice), atorvastatin (0.104 mg/20 g BW of mice), lovastatin (0.052 mg/20 g BW of mice), pitavastatin (0.010 mg/20 g BW of mice), pravastatin (0.052 mg/20 g BW of mice), rosuvastatin (0.052 mg/20 g BW of mice), and fluvastatin (0.208 mg/20 g BW of mice). The blood glucose test was carried out on days 30th and 60th. The results showed no significant difference in the blood glucose between the negatives group and all statin groups on days 30th and 60th. However, an increase in blood glucose on day 30th for pitavastatin, pravastatin, and rosuvastatin as much as 7.08%, 6.29%, and 6.29%, respectively. Moreover, an increase on day 60th for pravastatin, rosuvastatin, fluvastatin, atorvastatin lovastatin, and simvastatin as much as 36.83%, 27.59%, 26.32%, 18.05%, 17.89% dan 10.97%, respectively. This study failed to prove blood glucose elevation associated with a statin. The longer use of drugs was associated with blood glucose level elevation, except for pitavastatin. Therefore, further studies with a long term of statin administration are necessary.
References
WHO. Cardiovascular diseases (CVDs) key facts. World Heal Organ [Internet]. 2021;(June):1–5. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Watts GF, Catapano AL, Masana L, Zambon A, Pirillo A, Tokgözoglu L. Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atheroscler Suppl. 2020;42(2020):e30–4.
Yao YS, Li T Di, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: An updated review. Lipids Health Dis. 2020;19(1):1–6.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 139, Circulation. 2019. 1082–1143 p.
Kim DW, Kim DH, Park JH, Choi M, Kim S, Kim H, et al. Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. Diabetol Metab Syndr [Internet]. 2019;11(1):1–8. Available from: https://doi.org/10.1186/s13098-019-0427-9
Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction. Oxford Med Case Reports. 2018;2018(3):86–8.
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123–30.
Yoon D, Sheen SS, Lee S, Choi YJ, Park RW, Lim H-S. Statins and risk for new-onset diabetes mellitus. Medicine (Baltimore). 2016;95(46):e5429.
Galicia-Garcia U, Jebari S, Larrea-Sebal A, Uribe KB, Siddiqi H, Ostolaza H, et al. Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. Int J Mol Sci. 2020;21(13):1–25.
Hori E, Kikuchi C, Imaeda K, Okayama N, Suzuki T, Matsunagaa T. Effect of statins on glycemic status and plasma adiponectin concentrations in patients with type 2 diabetes mellitus and hypercholesterolemia. Yakugaku Zasshi. 2019;139(5):807–15.
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: Population based study. BMJ. 2013;346(7911):1–11.
Ko MJ, Jo AJ, Kim YJ, Kang SH, Cho S, Jo SH, et al. Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. J Am Heart Assoc. 2019;8(8).
Na E, Cho S, Kim DJ, Choi J, Han E. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: A retrospective cohort study. Cardiovasc Diabetol [Internet]. 2020;19(1):1–11. Available from: https://doi.org/10.1186/s12933-020-01037-0
Aygun S, Tokgozoglu L. Comparison of Current International Guidelines for the Management of Dyslipidemia. J Clin Med. 2022;11(23).
Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32(14):1769–818.
